Literature DB >> 6362866

Adoptive immunotherapy of cancer: accomplishments and prospects.

S A Rosenberg.   

Abstract

Adoptive immunotherapy is an approach to cancer treatment that has not received significant evaluation in cancer patients. Recent developments in modern cellular immunology have expanded the opportunities for utilizing adoptive immunotherapy in humans. A variety of animal models have been developed utilizing the adoptive transfer of immune cells that can mediate the regression of established murine tumors. Analyses of these models are defining the important criteria necessary for the application of this approach to humans. Studies of the immune response of human cells to autologous tumors are identifying cells with antitumor reactivity that may be of value in the treatment of human malignancy. Preliminary clinical studies have been performed demonstrating the feasibility of infusing large numbers of activated lymphoid cells into humans. Adoptive immunotherapy is an approach to the treatment of cancer that deserves further study.

Entities:  

Mesh:

Year:  1984        PMID: 6362866

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN: 0361-5960


  27 in total

1.  Pronounced antitumor effect of LAK-like cells induced in the peritoneal cavity of mice after intraperitoneal injection of OK-432, a killed streptococcal preparation.

Authors:  M Saito; O Ichimura; M Kataoka; Y Moriya; K Ueno; Y Sugawara; M Nanjo; N Ishida
Journal:  Cancer Immunol Immunother       Date:  1986       Impact factor: 6.968

2.  Phenotypic evolution of CTL B-lines in vitro.

Authors:  M Février; C Foa; J Simonetti; C Prevot; M Barad; M Berebbi
Journal:  Br J Exp Pathol       Date:  1987-04

Review 3.  Graft versus leukemia in bone marrow transplantation.

Authors:  M Boranić
Journal:  Blut       Date:  1988-08

4.  Natural killer and activated killer activities in chronic liver disease and hepatocellular carcinoma: evidence for a decreased lymphokine-induced activity of effector cells.

Authors:  H Hirofuji; S Kakumu; A Fuji; Y Ohtani; K Murase; H Tahara
Journal:  Clin Exp Immunol       Date:  1987-05       Impact factor: 4.330

5.  The toxicity of recombinant human interleukin-2 in rats following intravenous infusion.

Authors:  Y L Matory; A E Chang; E H Lipford; R Braziel; C L Hyatt; S A Rosenberg
Journal:  J Natl Med Assoc       Date:  1987-05       Impact factor: 1.798

Review 6.  The adoptive immunotherapy of cancer using lymphokine activated killer cells and recombinant interleukin-2.

Authors:  S E Ettinghausen; S A Rosenberg
Journal:  Springer Semin Immunopathol       Date:  1986

Review 7.  Immunotherapy for cancer: the use of lymphokine activated killer (LAK) cells.

Authors:  E A Fagan; A L Eddleston
Journal:  Gut       Date:  1987-02       Impact factor: 23.059

8.  Evaluation of in vivo and in vitro effectivity of immune defense against a spontaneously arising, nonlymphoid rat tumor. II. T cell response after induction of immunogenicity.

Authors:  M Zöller
Journal:  Cancer Immunol Immunother       Date:  1985       Impact factor: 6.968

9.  Matrix Metalloproteinase 8: Could it Benefit the CAR-T Cell Therapy of Solid Tumors?- a- Commentary on Therapeutic Potential.

Authors:  Alireza Mardomi; Saeid Abediankenari
Journal:  Cancer Microenviron       Date:  2018-03-27

10.  Preferential homing of tumor-infiltrating lymphocytes in tumor-bearing mice.

Authors:  I H Ames; G M Gagne; A M Garcia; P A John; G M Scatorchia; R H Tomar; J G McAfee
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.